Koers Relmada Therapeutics, Inc. OTC Markets
Aandelen
RLMD
US75955J4022
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,67 USD | 0,00% |
|
+8,91% | +139,13% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 114 mln. 104 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -102 mln. -93,33 mln. | Nettowinst (verlies) 2025 * | -120 mln. -110 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 159 mln. 146 mln. | Nettoliquiditeiten 2025 * | 89,3 mln. 81,71 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,25
x | K/w-verhouding 2025 * |
-1,46
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,96% |
Recentste transcriptie over Relmada Therapeutics, Inc.
1 dag | -66,18% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 31-05-12 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12-11-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 78 | 14-07-15 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 12-11-15 |
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,65% | 126 mld. | |
+22,98% | 118 mld. | |
+23,26% | 27,87 mld. | |
-19,15% | 20,95 mld. | |
-15,13% | 16,92 mld. | |
-14,35% | 16,18 mld. | |
+9,42% | 14,84 mld. | |
-46,10% | 14,79 mld. | |
+50,64% | 14,08 mld. |
- Beurs
- Aandelen
- Koers RLMD
- Koers RLMD